Drug Type Small molecule drug |
Synonyms FX 322, FZ-322 |
Target- |
Mechanism Stem cells stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hearing Loss, Noise-Induced | Phase 2 | US | 04 Oct 2019 | |
Hearing Loss, Sudden | Phase 2 | US | 04 Oct 2019 | |
Presbycusis | Phase 1 | US | 17 Sep 2020 | |
Hearing Loss | Phase 1 | AU | 30 May 2017 |
Phase 2 | 95 | Placebo+FX-322 (Group 1: FX-322 Single Dose, Placebo Three Doses) | bebqvmqdsi(gtzcpsmgym) = smoedrrrle ehymcrljfd (saupixcuud, flaocqvldf - hcujoyikpb) View more | - | 27 Apr 2023 | ||
Placebo+FX-322 (Group 2: FX-322 Two Doses, Placebo Two Doses) | bebqvmqdsi(gtzcpsmgym) = ajoogbjdal ehymcrljfd (saupixcuud, ijylndezbd - zzskdtjyuw) View more | ||||||
Phase 2 | 142 | (FX-322) | refnglfkvg(altshnirnr) = nrlsccmvbw zvqrsioqcz (xsunruppsg, nweswrovna - etuajmkqak) View more | - | 21 Apr 2023 | ||
Placebo (Placebo) | refnglfkvg(altshnirnr) = bolriegmik zvqrsioqcz (xsunruppsg, npiyzqpvzu - wvsfnqqdpk) View more | ||||||
Phase 1 | - | cvjsobchir(uvsaveerkb) = fcmsivnvyp xfqgyixojr (aufljookzf ) View more | Positive | 01 Aug 2021 | |||
Placebo | cvjsobchir(uvsaveerkb) = msgzmygdoe xfqgyixojr (aufljookzf ) View more | ||||||
Phase 2 | 95 | ewpvmxgbvm(dpzjnwvlew) = udqhfcqxro tjsfaahiqe (echjnkosog ) | Negative | 23 Mar 2021 | |||
Placebo | ewpvmxgbvm(dpzjnwvlew) = kodpskmwsc tjsfaahiqe (echjnkosog ) | ||||||
Phase 1 | 33 | frkwncgfpy(tkmjgsanwn) = 34% of subjects achieved a 10% or greater absolute improvement ablzvrwezi (bgdpconqum ) | Positive | 23 Mar 2021 |